• A blue image of letters and test tubes

    UTMB and HDT Bio awarded prototype project funding worth up to $87.4M from the U.S. government to develop saRNA vaccine technology

    The University of Texas Medical Branch (UTMB) has been awarded a project agreement worth up to $87.4 million by the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and the U.S. Department of Health and Human Services’ (HHS) Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response (ASPR), through the Medical CBRN Defense Consortium (MCDC) Other Transaction Authority (OTA), for the development of a vaccine technology against advanced and emerging viral threats. Two deadly viruses of significance to military personnel will be targeted for vaccine protection. These are Crimean-Congo hemorrhagic fever virus (CCHFV) and Nipah virus (NiV).

  • A set of car keys next to two shot glasses with amber colored liquor

    Staged ‘crash’ event asks ‘Is It Worth It?’

    Driving while drunk. Or under the influence of drugs. Or when your mind is on anything other than the road. Is it worth it? The answer to that question is a resounding no. University of Texas Medical Branch Trauma Services, in conjunction with The Center for Addiction Research, will drive home that point with a live production that vividly portrays the devastating effects of drunken/drugged driving.

  • UTMB Researchers Study COVID Outbreaks in Summer Camps

    Researchers at The University of Texas Medical Branch recently investigated a COVID-19 outbreak in an overnight camp in Texas to better understand transmission. The study revealed that the summer camp outbreak was most likely the result of a single introduction of the virus that spread throughout the camp, and then to the community.

  • Image of Nipah virus

    Study Proposes a Live Attenuated SARS-CoV-2 Vaccine Candidate

    In a new study published recently on Nature Communications, researchers engineered a live-attenuated SARS-CoV-2 vaccine candidate that could potentially be studied at biosafety level 2 for easier COVID-19 research and countermeasure development.

  • Scientists develop second-generation COVID-19 vaccine taken nasally

    As scientists race to create the next generation of COVID-19 vaccines, this UTMB/CUA research in mice adds new possibilities for fighting the disease in humans in the future. Nasal vaccination induces another type of an immune response which can effectively kill the pathogen at the port of entry, which is the respiratory tract for SARS-CoV-2. No injections are needed, and the vaccine can be delivered in a nasal spray.